Rosario Foti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5889993/publications.pdf

Version: 2024-02-01

471371 377752 1,194 43 17 34 citations h-index g-index papers 43 43 43 1948 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
2	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. Clinical Rheumatology, 2022, 41, 2261-2267.	1.0	7
3	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. Expert Opinion on Drug Safety, 2022, 21, 613-623.	1.0	3
4	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. Current Pharmaceutical Design, 2022, 28, 2022-2028.	0.9	7
5	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. Clinical Rheumatology, 2022, 41, 3219-3225.	1.0	3
6	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open, 2021, 7, e001519.	1.8	32
7	Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato, 2021, 2, 347-352.	0.2	0
8	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatology International, 2020, 40, 263-272.	1.5	10
9	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs, 2020, 80, 1929-1946.	4.9	74
10	Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19. Frontiers in Public Health, 2020, 8, 558838.	1.3	6
11	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.3	3
12	Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity. Diagnostics, 2020, 10, 404.	1.3	5
13	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. Clinical Rheumatology, 2019, 38, 2355-2362.	1.0	15
14	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
15	Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach. Advances in Therapy, 2019, 36, 806-816.	1.3	20
16	ABO761â€SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENCE 2019, , .	·· ,	0
17	AB0253â€BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		O
18	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Frontiers in Pharmacology, 2019, 10, 1497.	1.6	12

#	Article	IF	Citations
19	"Disease knowledge index―and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
20	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. Indian Journal of Rheumatology, 2019, 14, 271.	0.2	1
21	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 619-629.	1.6	9
22	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine, 2018, 85, 455-459.	0.8	14
23	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology, 2018, 57, vii11-vii22.	0.9	17
24	Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatology International, 2017, 37, 245-249.	1.5	19
25	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Seminars in Arthritis and Rheumatism, 2017, 47, 183-192.	1.6	63
26	Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study. Italian Journal of Dermatology and Venereology, 2017, 152, 297-301.	0.1	3
27	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 45, 519-532.	1.6	45
28	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood, 2015, 126, 1163-1171.	0.6	69
29	Long-term survival in a patient with muscle–eye–brain disease. Neurological Sciences, 2015, 36, 2147-2149.	0.9	3
30	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
31	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. Journal of Rheumatology, 2014, 41, 99-105.	1.0	73
32	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clinical Rheumatology, 2014, 33, 31-37.	1.0	10
33	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine, 2014, 81, 508-512.	0.8	21
34	Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care and Research, 2013, 65, 94-100.	1.5	170
35	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. Microvascular Research, 2013, 89, 122-128.	1.1	101
36	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134

Rosario Foti

#	Article	IF	CITATION
37	Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study. Clinical and Experimental Rheumatology, 2010, 28, 186-200.	0.4	23
38	Long-Term angiographic follow-up after successful repeat balloon angioplasty for in-stent restenosis. Clinical Cardiology, 2001, 24, 334-340.	0.7	4
39	Usefulness of exercise tomographic myocardial perfusion imaging for detection of restenosis after coronary stent implantation. American Journal of Cardiology, 2000, 85, 1362-1364.	0.7	28
40	Accuracy of exercise testing in the assessment of the severity of myocardial ischemia as determined by means of technetium-99m tetrofosmin SPECT scintigraphy. Journal of Nuclear Cardiology, 2000, 7, 575-583.	1.4	13
41	Accuracy of 99mTc-tetrofosmin myocardial tomography in the evaluation of coronary artery disease. Journal of Nuclear Cardiology, 1999, 6, 183-189.	1.4	27
42	Comparison of technetium 99m-tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. Journal of Nuclear Cardiology, 1998, 5, 56-63.	1.4	18
43	Cardiac hydatid cyst with clinical features resembling subaortic stenosis. American Heart Journal, 1989, 117, 1385-1387.	1.2	17